Shield Therapeutics plc (AIM:STX)

Market Cap	98.29M +225.4%
Revenue (ttm)	36.93M +54.4%
Net Income	-13.12M
EPS	-0.01
Shares Out	1.07B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	628,924
Average Volume	2,756,048
Open	9.35
Previous Close	9.35
Day's Range	9.20 - 9.50
52-Week Range	2.10 - 12.50
Beta	1.91
RSI	55.62
Earnings Date	Apr 24, 2026

About Shield Therapeutics

Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the United Kingdom.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2008
• Employees: 63
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: STX

Financial Performance

In 2025, Shield Therapeutics's revenue was $49.70 million, an increase of 54.45% compared to the previous year's $32.18 million. Losses were -$17.66 million, -35.05% less than in 2024.

Financial numbers in USD